(Q38106628)

29 August 2017

title

The role of phosphodiesterases in bladder pathophysiology (English)

1 reference

29 August 2017

1 reference

Mohammad S Rahnama'i

1

1 reference

29 August 2017

Stefan Ückert

series ordinal

2

1 reference

29 August 2017

Ramona Hohnen

series ordinal

3

1 reference

29 August 2017

Gommert A van Koeveringe

series ordinal

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

14 May 2013

1 reference

29 August 2017

published in

Nature Reviews Urology

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

414-424

1 reference

Cyclic GMP phosphodiesterases and regulation of smooth muscle function

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Molecular details of cAMP generation in mammalian cells: a tale of two systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Adenylyl cyclase--A-kinase anchoring protein complexes: the next dimension in cAMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

New insights into the pharmacology of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Immunohistochemical localization of peripheral nitric oxide synthase‐containing nerves using antibodies raised against synthesized C‐ and N‐terminal fragments of a cloned enzyme from rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Morphological and biochemical investigation of nitric oxide synthase and related enzymes in the rat and pig urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Distribution of phosphodiesterase I in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Selective inhibition of phosphodiesterase 1 relaxes urinary bladder smooth muscle: role for ryanodine receptor-mediated BK channel activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Nitric oxide inhibits arginine-vasotocin-induced increase of water osmotic permeability in frog urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The role of cyclic nucleotides in guinea-pig bladder contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: in vitro and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Role of nitric oxide/cyclic GMP pathway in regulating spontaneous excitations in detrusor smooth muscle of the guinea-pig bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The effect of sildenafil citrate on bladder outlet obstruction: a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Relaxant effects of sildenafil on the human isolated bladder neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Sildenafil influences lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Isoforms of mammalian adenylyl cyclase: multiplicities of signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Higher-order organization and regulation of adenylyl cyclases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The basis for drug treatment of the overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The future of the oral pharmacotherapy of male erectile dysfunction: things to come

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Regulation of cyclic nucleotides in the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Vardenafil Improves Urodynamic Parameters in Men With Spinal Cord Injury: Results From a Single Dose, Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Distribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary bladder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Molecular biological characterization of phosphodiesterase 3A from human corpus cavernosum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.101

Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate

31 March 2020

1 reference

12 December 2020

Guanylyl cyclases and signaling by cyclic GMP.

1 reference

12 December 2020

[Effects and mechanisms of phosphodiesterase type 5 inhibitors on rats with overactive bladder].

1 reference

12 December 2020

Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder

1 reference

12 December 2020

Molecular mechanism of cGMP-mediated smooth muscle relaxation

1 reference

12 December 2020

Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology.

1 reference

12 December 2020

The molecular biology of cyclic nucleotide phosphodiesterases.

1 reference

12 December 2020

Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation

1 reference

12 December 2020

Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells

1 reference

12 December 2020

Nitric oxide: physiology, pathophysiology, and pharmacology

1 reference

12 December 2020

Improvement of urodynamic indices by single dose oral tadalafil in men with supra sacral spinal cord injury.

1 reference

12 December 2020

Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder

1 reference

12 December 2020

Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.101

1 reference

Dimensions Publication ID

29 August 2017

1017901029

0 references

1 reference